The invention concerns a pharmaceutical tablet for oral administration, for the controlled release of alfuzosine chlorhydrate at the proximal segments of the gastrointestinal tract, characterised in that it consists of: a) a first layer (1) capable of swelling noticeably and rapidly in contact with aqueous biological liquids, said layer being produced by a mixture or a granule containing hydrophilic polymers constituting 5.0 to 90 % and preferably 10 to 85 % of the layer weight; b) a second layer (2) adjacent to or superposed on the first layer, in which is carried the alfuzosine chlorhydrate, this layer being formed with hydrophilic polymers and other auxiliary substances, so as to give to the preparation suitable compressibility properties and to enable the release of the alfuzosine chlorhydrate in a predetermined lapse of time; c) and optionally a third layer (3) obtained by compression and applied on layer (2), generally consisting in particular of hydrophilic polymers which gel and/or swell and then can be optionally eroded and acting as a barrier modulating the release of the alfuzosine of layer (2), layer (3) being almost impermeable to the passage of the active substance. The invention is applicable to a pharmaceutical composition.

Tablet with controlled-release release of alfuzosin hydrochloride

MAGGI, LAURETTA;CONTE, UBALDO;
2000-01-01

Abstract

The invention concerns a pharmaceutical tablet for oral administration, for the controlled release of alfuzosine chlorhydrate at the proximal segments of the gastrointestinal tract, characterised in that it consists of: a) a first layer (1) capable of swelling noticeably and rapidly in contact with aqueous biological liquids, said layer being produced by a mixture or a granule containing hydrophilic polymers constituting 5.0 to 90 % and preferably 10 to 85 % of the layer weight; b) a second layer (2) adjacent to or superposed on the first layer, in which is carried the alfuzosine chlorhydrate, this layer being formed with hydrophilic polymers and other auxiliary substances, so as to give to the preparation suitable compressibility properties and to enable the release of the alfuzosine chlorhydrate in a predetermined lapse of time; c) and optionally a third layer (3) obtained by compression and applied on layer (2), generally consisting in particular of hydrophilic polymers which gel and/or swell and then can be optionally eroded and acting as a barrier modulating the release of the alfuzosine of layer (2), layer (3) being almost impermeable to the passage of the active substance. The invention is applicable to a pharmaceutical composition.
2000
The Chemistry category includes resources that are general in nature and cover a broad spectrum of topics in the chemical sciences. Resources specifically covering analytical chemistry, inorganic and nuclear chemistry, organic chemistry, physical chemistry, and polymer science will be placed in those particular categories. Miscellaneous and applied chemistry resources may be placed in this category when not appropriate for specific subfields in chemistry.
Us6149940
ELETTRONICO
Inglese
Internazionale
CONTROLLED RELEASE; MULTI LAYER TABLET
On this patent the following product was developped Uroxatral® in the US, a once-daily version of Sanofi-Aventis' Xatral®, a selective alpha-blocker for treating the urinary symptoms of benign prostatic hyperplasia
6 Brevetti::6.1 Brevetto
none
Maggi, Lauretta; Conte, Ubaldo; Grenier, P.; Vergnault, G.; Dofour, A.; Jarreau, F. X.; Rauch Desanti, C.
info:eu-repo/semantics/patent
285
7
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/461822
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact